Pharmaceutical

Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in…

1 year ago

Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M

Crossject to amend the Heights Capital Management, Inc. (“Heights”) bonds convertible in new shares or repayable Dijon, FRANCE, December 11,…

1 year ago

Waterdrop Inc. Announces Third Quarter 2024 Unaudited Financial Results

BEIJING, Dec. 11, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated…

1 year ago

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin…

1 year ago

Pharmacy Benefit Managers: Driving Cost Savings and Innovation in Healthcare

Real value in working with Canada Drugs Direct as a partner pharmacy that is able to serve as a PBM…

1 year ago

Rapid Dose Announces Proposed Equity Private Placement Financing and Proposed Shares for Debt Settlement

Burlington, Ontario--(Newsfile Corp. - December 10, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that…

1 year ago

Healthier Capital Led by Former One Medical CEO Invests in Hyro’s Responsible AI Agents for Healthcare

New growth capital, taking total raised by Hyro to $50 million, will advance leading conversational and generative AI solutions across…

1 year ago

Dotmatics and Databricks Partner to Advance Scientific Intelligence in Life Sciences

The strategic partnership combines Dotmatics' deep expertise in scientific software with Databricks data intelligence expertise An upcoming webinar with Databricks…

1 year ago

Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN

Admission of New Ordinary Shares and New ISIN LONDON, UNITED KINGDOM / ACCESSWIRE / December 10, 2024 / Hemogenyx Pharmaceuticals…

1 year ago

MIRA Pharmaceuticals Validates Ketamir-2’s Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain MIAMI, FL / ACCESSWIRE /…

1 year ago